EUVIMEDObjevte EUVIMED
Open access

Long-Term Empagliflozin Treatment (50 Days) Attenuates Protease Activity, Migration, and Stemness-Associated Phenotypes in BFTC-909 Renal Pelvis Transitional Cell Carcinoma Cells

Yi-Hsun Lee, Pei-Ni Chen, Yi-Hsien Hsieh, Yi-Cheng Chu, Li-Jeng Chen, Chin-Yin Lin, Shun-Fa Yang, Horng-Rong Chang

Journal of Cancer · 2026-07-13 · 17 (7) · 1373-1383

DOI: 10.7150/jca.132959 ↗

At a glance

Journal article in Journal of Cancer, published on 2026-07-13. Written by Yi-Hsun Lee and 7 co-authors. Institution: Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. The full text is freely available in PubMed Central.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Empagliflozin is a sodium-glucose cotransporter 2 inhibitor widely prescribed for the treatment of type 2 diabetes mellitus. It promotes urinary glucose excretion by inhibiting renal glucose reabsorption. Although empagliflozin has been widely used in clinical practice, its effects and underlying mechanisms related to metastasis, cytokine secretion, and stemness-associated phenotypes in renal pelvis transitional cell carcinoma (TCC) remain poorly understood. In this study, we investigated the long-term (50 days) effects of empagliflozin (5 μM) on BFTC-909 human renal pelvis TCC cells. Prolonged empagliflozin treatment suppressed the migration of tumor cells and the proteolytic activities of matrix metalloproteinase-2 and urokinase-type plasminogen activator. In addition, empagliflozin markedly reduced the viability and self-renewal capacity of BFTC-909 cells. Analysis of conditioned media revealed that long-term empagliflozin exposure significantly reduced the secretion of interleukin-1Ra, interleukin-8, granulocyte colony-stimulating factor, and vascular endothelial growth factor. Together, these findings suggest that empagliflozin suppresses the protease activity, tumor invasiveness, and stemness-associated phenotypes of renal pelvis TCC cells. Overall, this study indicates that long-term empagliflozin treatment reduces the metastatic potential of BFTC-909 renal pelvis TCC cells and highlights the need for additional in vivo and clinical investigations.

Subjects

Author keywords

empagliflozininvasionmatrix metalloproteinase-2metastasisstemness-associated phenotypes

Authors and institutions

  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Division of Nephrology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • School of Medicine, Chung Shan Medical University, Taichung, Taiwan.

Cite

APA

Lee, Y. H., Chen, P. N., Hsieh, Y. H., Chu, Y. C., Chen, L. J., Lin, C. Y., Yang, S. F., & Chang, H. R. (2026). Long-Term Empagliflozin Treatment (50 Days) Attenuates Protease Activity, Migration, and Stemness-Associated Phenotypes in BFTC-909 Renal Pelvis Transitional Cell Carcinoma Cells. Journal of Cancer, 17(7), 1373-1383. https://doi.org/10.7150/jca.132959

Vancouver

Lee YH, Chen PN, Hsieh YH, Chu YC, Chen LJ, Lin CY, et al. Long-Term Empagliflozin Treatment (50 Days) Attenuates Protease Activity, Migration, and Stemness-Associated Phenotypes in BFTC-909 Renal Pelvis Transitional Cell Carcinoma Cells. Journal of Cancer. 2026;17(7):1373-1383. doi:10.7150/jca.132959

BibTeX
@article{Lee2026,
  author = {Lee, Yi-Hsun and Chen, Pei-Ni and Hsieh, Yi-Hsien and Chu, Yi-Cheng and Chen, Li-Jeng and Lin, Chin-Yin and Yang, Shun-Fa and Chang, Horng-Rong},
  title = {Long-Term Empagliflozin Treatment (50 Days) Attenuates Protease Activity, Migration, and Stemness-Associated Phenotypes in BFTC-909 Renal Pelvis Transitional Cell Carcinoma Cells},
  journal = {Journal of Cancer},
  year = {2026},
  volume = {17},
  number = {7},
  pages = {1373--1383},
  doi = {10.7150/jca.132959}
}
Start for free →